Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 3/20 | 0.57 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.42 |
| ▸ | DHFR | P00374 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | BCL6 | P41182 | 1/20 | 0.36 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL654571 | 0.86 | SYK (0.45) | SYKADORA1DHFR | |
| SCHEMBL4801395 | 0.85 | SYK (0.76) | SYKADORA1DHFRCYP3A4BCL6 | |
| SCHEMBL4805600 | 0.83 | SYK (0.57) | SYKDHFRBCL6 | |
| SCHEMBL4801741 | 0.83 | SYK (0.57) | SYKADORA1DHFRTSHRBCL6 | |
| SCHEMBL4802062 | 0.83 | SYK (0.57) | SYKADORA1DHFRBCL6KMT2A | |
| SCHEMBL4801168 | 0.82 | SYK (0.54) | SYKADORA1ALDH1A1CYP3A4TSHR | |
| SCHEMBL27612623 | 0.80 | SYK (0.53) | SYKDHFRBCL6RPS6KA3ADORA2A | |
| SCHEMBL654327 | 0.78 | SYK (0.49) | SYKDHFRALDH1A1RPS6KA3 | |
| SCHEMBL27631778 | 0.77 | SYK (0.50) | SYKBCL6RPS6KA3TDP1 | |
| SCHEMBL4798557 | 0.75 | SYK (0.48) | SYKDHFRALDH1A1BCL6RPS6KA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10682350-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2020-06-16 | — | — | US | disclosed |
| CN-110404062-A | Immunomodulator and application thereof | UNIV QUEENSLAND | 2019-11-05 | — | — | CN | disclosed |
| US-9133133-B2 | 2,4-pyridinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2015-09-15 | — | — | US | disclosed |
| US-20150126504-A1 | 2,4-Pyrimidinediamine Compounds and Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2015-05-07 | — | — | US | disclosed |
| US-9018204-B1 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2015-04-28 | — | — | US | disclosed |
| US-20150005297-A1 | 2,4-Pyrimidinediamine Compounds and Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2015-01-01 | — | — | US | disclosed |
| US-20140330007-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2014-11-06 | — | — | US | disclosed |
| US-20140303154-A1 | 2,4-PYRIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2014-10-09 | — | — | US | disclosed |
| US-20130317216-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | MIDCAP FINANCIAL TRUST | 2013-11-28 | — | — | US | disclosed |
| US-8334296-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2012-12-18 | — | — | US | disclosed |
| US-7498435-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2009-03-03 | — | — | US | disclosed |
| US-7485724-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2009-02-03 | — | — | US | disclosed |
| US-20070293524-A1 | Salts, hydrates, solvatesand/or N-oxides; inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators; Syk kinase inhibitors; inhibiting an Fc receptor signal transduction cascade | RIGEL PHARMACEUTICALS, INC. (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070293520-A1 | One amine is substituted with a fused heterocyclic ring and the other with a fused heterocyclic ring or phenyl ring, e.g., N2,N4-Bis(3,4-ethylenedioxyphenyl)-5-cyano-2,4-pyrimidinediamine; inhibit IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators such as histamine | RIGEL PHARMACEUTICALS, INC. (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070293523-A1 | inhibitors of immunoglobulin E or G receptor signaling cascades; Syk kinase inhibitors; use as antiallergic, antiinflammatory agents | RIGEL PHARMACEUTICALS, INC. (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070293522-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070225321-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2007-09-27 | — | — | US | disclosed |
| EP-1786783-A1 | SYNTHESIS OF 2,4-PYRIMIDINEDIAMINE COMPOUNDS | Rigel Pharmaceuticals, Inc. (US) | 2007-05-23 | — | — | EP | disclosed |
| WO-2006028833-A1 | SYNTHESIS OF 2,4-PYRIMIDINEDIAMINE COMPOUNDS | RIGEL PHARMACEUTICALS, INC. (US) | 2006-03-16 | — | — | WO | disclosed |
| CN-1678321-A | Methods of treating or preventing autoimmune diseases with 2, 4-pyrimidinediamine compounds | RIGEL PHARMACEUTICALS INC (US) | 2005-10-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303154-A1 | 2,4-PYRIDINEDIAMINE COMPOUNDS AND THEIR USES | FCER2, FCGR1A, FCGR2A | SYK 38/4885ADORA1 196/4885DHFR 947/4885 |
| US-20150005297-A1 | 2,4-Pyrimidinediamine Compounds and Their Uses | FCER2, FCGR1A, FCGR2A | SYK 54/4885ADORA1 77/4885DHFR 233/4885 |
| US-20070225321-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | FCER2, FCGR1A, FCGR2A | SYK 54/4885ADORA1 77/4885DHFR 233/4885 |
| US-20130317216-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | FCER2, FCGR1A, FCGR2A | SYK 54/4885ADORA1 77/4885DHFR 233/4885 |
| US-10682350-B2 | 2,4-pyrimidinediamine compounds and their uses | FCER2, FCGR1A, FCGR2A | SYK 54/4885ADORA1 77/4885DHFR 233/4885 |
| US-20150126504-A1 | 2,4-Pyrimidinediamine Compounds and Their Uses | FCER2, FCGR1A, FCGR2A | SYK 54/4885ADORA1 77/4885DHFR 233/4885 |
| US-20070293523-A1 | inhibitors of immunoglobulin E or G receptor signaling cascades; Syk kinase inhibitors; use as antiallergic, antiinflammatory agents | FCER2, SYK, FCGR1A | SYK 2/4885ADORA1 196/4885DHFR 943/4885 |
| US-20140330007-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | FCER2, FCGR1A, FCGR2A | SYK 54/4885ADORA1 77/4885DHFR 233/4885 |
| US-20070293522-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | FCER2, FCGR1A, FCGR2A | SYK 54/4885ADORA1 77/4885DHFR 233/4885 |
| US-20070293520-A1 | One amine is substituted with a fused heterocyclic ring and the other with a fused heterocyclic ring or phenyl ring, e.g., N2,N4-Bis(3,4-ethylenedioxyphenyl)-5-cyano-2,4-pyrimidinediamine; inhibit IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators such as histamine | HRH4, FCER2, HRH2 | SYK 78/4885ADORA1 175/4885DHFR 578/4885 |
| US-20070293524-A1 | Salts, hydrates, solvatesand/or N-oxides; inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators; Syk kinase inhibitors; inhibiting an Fc receptor signal transduction cascade | SYK, FCER2, FCGR1A | SYK 1/4885ADORA1 817/4885DHFR 1523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.